Page 41 - Bio Developments News Today

The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.

The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.

The non-digestible polysaccharide Arabinoxylan may be an effective oral adjuvant to support vaccine efficacy, according to a new pilot study involving 231 elderly participants.

Shoreline Biosciences and BeiGene collaborate on genetically modified natural killer cell therapies Shoreline Biosciences and BeiGene have announced an exclusive worldwide strategic collaboration to develop and commercialize a portfolio of natural killer (NK) based cell therapeutics. The partnership will focus on a portfolio of NK-based cell therapeutics, using San Diego, California-headquartered Shoreline’s iPSC-derived NK cell tech. Shoreline will receive an upfr...

COVID-19 vaccination via Vaxxas’ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.

A Phase 3 study of BAT1806, a proposed biosimilar referencing Actemra/RoActemra (tocilizumab), has shown equivalent efficacy and a comparable safety profile in patients with moderate-to-severe rheumatoid arthritis.

Engine Biosciences, a Singapore- and Silicon Valley-based company with an artificial intelligence-enabled technology platform that is designed to discover new biology targets and disease-causing links amongst known targets, has generated US$43m in a Series A funding round.

Pfizer has enrolled the first subjects in a study exploring the co-administration of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 vaccine. The trial will cover a cohort of 600 adults aged 65+, taken from last year’s COVID-19 Phase 3 vaccine trial. Having received their second dose of the COVID-19 vaccine at least six months ago, participants will be randomized into groups to receive either...

Nanoparticle based shot could boost efficacy, accelerate production of seasonal flu vaccines Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC). An experimental recombinant protein nanoparticle vaccine that stimulates a strong immune response is hoping to address that inefficiency. Key to the vaccines success is a liposome the developers created called cobalt-porphyrin-phospholipid, or CoPoP....

Pfizer and AstraZeneca COVID-19 vaccines are ‘highly effective’ against India variant Vaccine effectiveness against symptomatic disease from the B.1.617.2 (‘India’) variant is similar to that found against the B.1.1.7 (UK) variant, according to a new study. The Pfizer/BioNTech vaccine was found to be 88% effective against B.1.617.2 two weeks after the second dose; compared to 93% effectiveness against the B.1.1.7 variant. Meanwhile, two doses of the AstraZene...